Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
| Revenue (Most Recent Fiscal Year) | $76.30M |
| Net Income (Most Recent Fiscal Year) | $-122.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.16 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -41.69% |
| Net Margin (Trailing 12 Months) | -47.16% |
| Return on Equity (Trailing 12 Months) | -19.25% |
| Return on Assets (Trailing 12 Months) | -14.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 74.84M |
| Free Float | 49.76M |
| Market Capitalization | $1.96B |
| Average Volume (Last 20 Days) | 1.95M |
| Beta (Past 60 Months) | 1.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.51% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |